Considerations Regarding the Use of Blood Samples in the Proteomic Identification of Biomarkers for Cancer Diagnosis

Blood is the most common source of biomarkers for use in the diagnosis and prognosis of malignant disease. Utilizing proteomic technology for biomarker identification offers greatly increased sensitivity. Such an increase in sensitivity requires precise sample preparation to eliminate any bias in an...

Full description

Saved in:
Bibliographic Details
Published inCancer genomics & proteomics Vol. 3; no. 3-4; p. 227
Main Authors CHRISTINE V. SAPAN, ROGER L. LUNDBLAD
Format Journal Article
LanguageEnglish
Published International Institute of Anticancer Research 01.05.2006
Online AccessGet full text

Cover

More Information
Summary:Blood is the most common source of biomarkers for use in the diagnosis and prognosis of malignant disease. Utilizing proteomic technology for biomarker identification offers greatly increased sensitivity. Such an increase in sensitivity requires precise sample preparation to eliminate any bias in analysis. Here, issues concerning the use of blood, plasma and serum for proteomic analysis are summarized.
ISSN:1109-6535